Passage BIO, Inc S-4/A, filed Oct 5, 2026

Passage BIO, Inc. (PASG)

Passage Bio proposes mergers making Remix Therapeutics a subsidiary, rename the combined company Remix Therapeutics, and conduct a concurrent financing expected to yield approximately $100.0 million in gross proceeds. Stockholders will vote on November 5, 2026. AI summary